AN2 Therapeutics, Inc. (ANTX)
NASDAQ: ANTX · Real-Time Price · USD
1.300
+0.240 (22.64%)
Nov 20, 2024, 4:00 PM EST - Market closed
AN2 Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Cash & Equivalents | 33.5 | 15.65 | 27.22 | 12.1 | 4.07 | 5.6 |
Short-Term Investments | 59.92 | 91.65 | 68.84 | 46.46 | - | - |
Cash & Short-Term Investments | 93.43 | 107.3 | 96.06 | 58.56 | 4.07 | 5.6 |
Cash Growth | -24.55% | 11.70% | 64.05% | 1338.70% | -27.30% | - |
Prepaid Expenses | 4.26 | 3.21 | 2.51 | 1.55 | 0.16 | 0.02 |
Other Current Assets | - | - | 0.05 | - | - | 0.08 |
Total Current Assets | 97.69 | 110.51 | 98.62 | 60.11 | 4.23 | 5.7 |
Long-Term Investments | - | 27.19 | 3.22 | 3.49 | - | - |
Long-Term Deferred Charges | - | - | - | 1.72 | - | - |
Other Long-Term Assets | - | 1.04 | 0.72 | - | - | - |
Total Assets | 97.69 | 138.74 | 102.56 | 65.32 | 4.23 | 5.7 |
Accounts Payable | 1.71 | 2.68 | 2.12 | 1.06 | 0.13 | 0.05 |
Accrued Expenses | 7.03 | 10.7 | 5.01 | 2 | 1.31 | 0.11 |
Current Portion of Leases | - | - | 0.05 | - | - | - |
Other Current Liabilities | 1.28 | 0.67 | 0.01 | 0.33 | 0.01 | - |
Total Current Liabilities | 10.02 | 14.04 | 7.19 | 3.4 | 1.46 | 0.16 |
Long-Term Debt | - | - | - | - | - | 0.73 |
Other Long-Term Liabilities | - | - | 0 | 0.01 | 0.02 | - |
Total Liabilities | 10.02 | 14.04 | 7.19 | 3.41 | 1.48 | 0.89 |
Additional Paid-In Capital | 285.81 | 278.88 | 185.47 | - | - | - |
Retained Earnings | -198.25 | -154.46 | -89.72 | -47.38 | -20.32 | -5.8 |
Comprehensive Income & Other | 0.11 | 0.28 | -0.37 | -0.03 | - | - |
Total Common Equity | 87.67 | 124.7 | 95.37 | -47.41 | -20.32 | -5.8 |
Shareholders' Equity | 87.67 | 124.7 | 95.37 | 61.91 | 2.75 | 4.81 |
Total Liabilities & Equity | 97.69 | 138.74 | 102.56 | 65.32 | 4.23 | 5.7 |
Total Debt | - | - | 0.05 | - | - | 0.73 |
Net Cash (Debt) | 93.43 | 107.3 | 96.01 | 58.56 | 4.07 | 4.87 |
Net Cash Growth | -24.55% | 11.76% | 63.96% | 1338.70% | -16.43% | - |
Net Cash Per Share | 3.13 | 4.55 | 6.26 | 22.20 | 1.58 | 1.91 |
Filing Date Shares Outstanding | 29.88 | 29.77 | 19.4 | 2.73 | 2.71 | 2.55 |
Total Common Shares Outstanding | 29.88 | 29.74 | 19.4 | 2.73 | 2.71 | 2.55 |
Working Capital | 87.67 | 96.46 | 91.44 | 56.71 | 2.78 | 5.54 |
Book Value Per Share | 2.93 | 4.19 | 4.92 | -17.36 | -7.50 | -2.27 |
Tangible Book Value | 87.67 | 124.7 | 95.37 | -47.41 | -20.32 | -5.8 |
Tangible Book Value Per Share | 2.93 | 4.19 | 4.92 | -17.36 | -7.50 | -2.27 |
Source: S&P Capital IQ. Standard template. Financial Sources.